Skip to main content
Clinical Trials/2024-518544-21-00
2024-518544-21-00
Recruiting
Phase 4

A Randomised controlled trial to compare efficacy and tolerability of Plenvu® and Picoprep® as cleansing agents before colonoscopy

Aalborg University Hospital1 site in 1 country400 target enrollmentStarted: November 5, 2024Last updated:

Overview

Phase
Phase 4
Status
Recruiting
Enrollment
400
Locations
1
Primary Endpoint
Efficacy of plenvu is not inferior to picoprep

Overview

Brief Summary

Aim of the study is to compare the efficacy and tolerability of the relatively new bowel preparation Plenvu® with the well established bowel preparation Picoprep® as cleansing agents before colonoscopy. This is to test whether the low volume Polyethylin Glycol-electrolytes lavage solution preparation Plenvu® would have non-inferior efficacy on bowel preparation compared with Picosulfate based Picoprep® with a better effect on compliance and tolerability.

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Ambulant colonoscopy
  • Older than18

Exclusion Criteria

  • Younger than 18
  • Patients with Phenylketonuria
  • Patients with Glucose-6-phosphate-dehydrogenase deficiency
  • Patients with rectum and/or colon resections
  • Known with severe heart failure
  • Known with severe renal failure (eGFR<30)*
  • Known with colonic stenosis
  • Pregnant or breastfeeding
  • Acute colonoscopy
  • Cancer screening program colonoscopy

Outcomes

Primary Outcomes

Efficacy of plenvu is not inferior to picoprep

Efficacy of plenvu is not inferior to picoprep

Secondary Outcomes

  • Tolerability of plenvu is not inferior to picoprep

Investigators

Sponsor Class
Hospital/Clinic/Other health care facility
Responsible Party
Principal Investigator
Principal Investigator

Hayder Alqaisi

Scientific

Aalborg University Hospital

Study Sites (1)

Loading locations...

Similar Trials